<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00879879</url>
  </required_header>
  <id_info>
    <org_study_id>SCUSF 0108 Pilot</org_study_id>
    <secondary_id>SCUSF-PILOT-0108</secondary_id>
    <secondary_id>5U10CA081920</secondary_id>
    <nct_id>NCT00879879</nct_id>
  </id_info>
  <brief_title>Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>Treatment of Idiopathic Pulmonary Fibrosis With Losartan: A Pilot Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Losartan may be effective in treating patients with idiopathic pulmonary fibrosis.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying the side effects of losartan and to see how well it&#xD;
      works in treating patients with idiopathic pulmonary fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Evaluate the effects of losartan potassium on disease progression in patients with&#xD;
           idiopathic pulmonary fibrosis.&#xD;
&#xD;
        -  Determine the safety of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral losartan potassium daily for 1 year in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo pulmonary function tests with gas diffusion lung volumes, Carbon monoxide&#xD;
      diffusing capacity (DLCO) tests, and 6-minute walk tests at baseline and then at 3, 6, 9, and&#xD;
      12 months. Patients also complete baseline/transition dyspnea index questionnaires at&#xD;
      baseline and then at 1, 3, 6, 9, and 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Stable or Improved Forced Vital Capacity (FVC) Response at 1 Year</measure>
    <time_frame>1 year</time_frame>
    <description>Forced vital capacity (FVC) must be &gt;= 50% at baseline. Stable FVC response is defined as a -5% change in FVC from baseline up to a +5% change from baseline.&#xD;
Improved FVC response is defined as 5% or greater increase in the predicted value of FVC on pulmonary function testing following 12 months of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Stable, Improved, or Deteriorated Diffusion Capacity of Carbon Monoxide (DLCO) at 1 Year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Stable, Improved or Deteriorated Forced Expiratory Volume at 1 Second (%FEV1) at 1 Year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Stable, Improved or Deteriorated Baseline/Transition Dyspnea Index at 1 Year</measure>
    <time_frame>1 year</time_frame>
    <description>This index measures a patient's degree of breathlessness related to their activities of daily living including their functional impairment and their magnitude of task and effort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Stable, Improved or Deteriorated 6-minute Walk Test Results at 1 Year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Precancerous Condition</condition>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg tablets of losartan taken daily by mouth for 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>losartan</intervention_name>
    <description>50 mg losartan taken daily by mouth in capsule form for 1 year</description>
    <arm_group_label>Losartan</arm_group_label>
    <other_name>losartan potassium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          -  Age &gt; 21 years&#xD;
&#xD;
          -  Diagnosis of idiopathic pulmonary fibrosis&#xD;
&#xD;
          -  Patients taking Coumadin and/or N-acetylcysteine may participate in the study&#xD;
&#xD;
          -  Baseline forced vital capacity (FVC) must be greater than or equal to 50%&#xD;
&#xD;
          -  Baseline 6 minute walk test distance walked must be greater than or equal to 200&#xD;
             meters not requiring greater than 6 lpm of oxygen&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Pregnant, intending to become pregnant or breastfeeding&#xD;
&#xD;
          -  Current or previous smoker of cigarettes or marijuana that recently quit within the&#xD;
             last 6 months prior to enrollment&#xD;
&#xD;
          -  Allergy or allergic reaction to Losartan or any other angiotensin II receptor blocker&#xD;
&#xD;
          -  Taking losartan or any other angiotensin II receptor blocker&#xD;
&#xD;
          -  Baseline systolic blood pressure &lt; 100 mmHg&#xD;
&#xD;
          -  Currently taking or has taken immunosuppressant agents within the last month such as&#xD;
             azathioprine, cyclophosphamide, colchicine and/or prednisone&#xD;
&#xD;
          -  History of lung transplant&#xD;
&#xD;
          -  History of kidney failure or liver disease&#xD;
&#xD;
          -  Inability to attend clinic visits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marisa Couluris, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>April 10, 2009</study_first_submitted>
  <study_first_submitted_qc>April 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2009</study_first_posted>
  <results_first_submitted>August 9, 2013</results_first_submitted>
  <results_first_submitted_qc>August 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 14, 2013</results_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>precancerous condition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precancerous Conditions</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects recruited from SunCoast Community Clinical Oncology Program (CCOP) Research Base affiliated CCOP members located in the United States.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Losartan</title>
          <description>50 mg tablets of losartan taken daily by mouth for 1 year&#xD;
losartan : 50 mg losartan taken daily by mouth in capsule form for 1 year</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Losartan</title>
          <description>50 mg tablets of losartan taken daily by mouth for 1 year&#xD;
losartan : 50 mg losartan taken daily by mouth in capsule form for 1 year</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="6.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FVC% Predicted</title>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.96" spread="3.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DLCO% Predicted</title>
          <units>Percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.65" spread="16.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>6MWT Distance</title>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="464.89" spread="249.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic O2 Supplementation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Stable or Improved Forced Vital Capacity (FVC) Response at 1 Year</title>
        <description>Forced vital capacity (FVC) must be &gt;= 50% at baseline. Stable FVC response is defined as a -5% change in FVC from baseline up to a +5% change from baseline.&#xD;
Improved FVC response is defined as 5% or greater increase in the predicted value of FVC on pulmonary function testing following 12 months of treatment.</description>
        <time_frame>1 year</time_frame>
        <population>Patients who received losartan for 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>50 mg tablets of losartan taken daily by mouth for 1 year&#xD;
losartan : 50 mg losartan taken daily by mouth in capsule form for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stable or Improved Forced Vital Capacity (FVC) Response at 1 Year</title>
          <description>Forced vital capacity (FVC) must be &gt;= 50% at baseline. Stable FVC response is defined as a -5% change in FVC from baseline up to a +5% change from baseline.&#xD;
Improved FVC response is defined as 5% or greater increase in the predicted value of FVC on pulmonary function testing following 12 months of treatment.</description>
          <population>Patients who received losartan for 12 months</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deteriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Stable, Improved, or Deteriorated Diffusion Capacity of Carbon Monoxide (DLCO) at 1 Year</title>
        <time_frame>1 year</time_frame>
        <population>Patients who received losartan for 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>50 mg tablets of losartan taken daily by mouth for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Stable, Improved, or Deteriorated Diffusion Capacity of Carbon Monoxide (DLCO) at 1 Year</title>
          <population>Patients who received losartan for 12 months.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deteriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Stable, Improved or Deteriorated Forced Expiratory Volume at 1 Second (%FEV1) at 1 Year</title>
        <time_frame>1 year</time_frame>
        <population>Patients who received losartan for 12 months</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>50 mg tablets of losartan taken daily by mouth for 1 year&#xD;
losartan : 50 mg losartan taken daily by mouth in capsule form for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Stable, Improved or Deteriorated Forced Expiratory Volume at 1 Second (%FEV1) at 1 Year</title>
          <population>Patients who received losartan for 12 months</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Stable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Deteriorated</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Stable, Improved or Deteriorated Baseline/Transition Dyspnea Index at 1 Year</title>
        <description>This index measures a patient's degree of breathlessness related to their activities of daily living including their functional impairment and their magnitude of task and effort.</description>
        <time_frame>1 year</time_frame>
        <population>Patients who received losartan for 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>50 mg tablets of losartan taken daily by mouth for 1 year</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Stable, Improved or Deteriorated Baseline/Transition Dyspnea Index at 1 Year</title>
          <description>This index measures a patient's degree of breathlessness related to their activities of daily living including their functional impairment and their magnitude of task and effort.</description>
          <population>Patients who received losartan for 12 months.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Stable</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Deteriorated</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Stable, Improved or Deteriorated 6-minute Walk Test Results at 1 Year</title>
        <time_frame>1 year</time_frame>
        <population>Patients who received losartan for 12 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Losartan</title>
            <description>50 mg tablets of losartan taken daily by mouth for 1 year&#xD;
Change in secondary markers of lung function over 12 months of losartan therapy, N=17&#xD;
N (%) Stable 6 (35.29) Improved 5 (29.41) Deteriorated 6 (-1.38)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Stable, Improved or Deteriorated 6-minute Walk Test Results at 1 Year</title>
          <population>Patients who received losartan for 12 months.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deteriorated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Losartan</title>
          <description>50 mg tablets of losartan taken daily by mouth for 1 year&#xD;
losartan : 50 mg losartan taken daily by mouth in capsule form for 1 year</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Death due to disease progression</sub_title>
                <description>1 subject died after 6 months on study. Death was deemed due to disease progression and unrelated to study procedures/study agent.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>1 subject experienced fatigue that resolved shortly after presentation.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <description>1 subject experienced a rash on study that resolved shortly after presentation.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A future phase II study is necessary to establish losartan's effect on IPF, due to a small number of patients and lack of controls to establish statistically significant efficacy.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jeffrey Krischer, Principal Investigator</name_or_title>
      <organization>SunCoast CCOP Research Base</organization>
      <phone>813-396-9245</phone>
      <email>ccop@epi.usf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

